Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)

NCT05282901 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG: Pembrolizumab 25 MG/1 ML Intravenous Solution

Sponsor

Institut Curie

Collaborators

[object Object]